A compound having the formula I wherein the O-(CH<；SUB>；2<；/SUB>；)<；SUB>；n<；/SUB>；-N(R<；SUP>；1<；/SUP>；,R<；SUP>；2<；/SUP>；) substituent on the phenyl ring can be in meta or para position； n is 2-4 R<；SUP>；e <；/SUP>；and 'R<；SUP>；e <；/SUP>；are OH, optionally independently etherified or esterified； R<；SUP>；1 <；/SUP>；and R<；SUP>；2 <；/SUP>；are independently (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(2C-4C)alkyl, (1C-3C)alkoxy(2C-4C)alkyl, aryl or aryl(1C-2C)alkyl； or R<；SUP>；1 <；/SUP>；and R<；SUP>；2 <；/SUP>；together with the nitrogen form an aromatic or non-aromatic heterocyclic ring structure, optionally mono- or poly-substituted with (1C-4C)alkyl, (2C-4C)alkenyl, hydroxy(1C-2C)alkyl, (1C-2C)alkoxy(1C-3C)alkyl or aryl. These compounds can be used for estrogen receptor P selective medical treatments.
